$DCOY

Decoy Therapeutics (NASDAQ:DCOY) said its IP portfolio grew to seven patent families and 19 pending applications in seven jurisdictions, including one granted U.S. patent. The filings cover antiviral peptide conjugates, peptide synthesis and linker methods, and compounds targeting conserved viral fusion protein features, including measles and Nipah. The company also filed a June 2026 application tied to its IMPACT platform.

Decoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001615219 false 0001615219 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14,

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

Decoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 dcoy-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 26, 2026, between Decoy Therapeutics Inc., a Delaware corporation (the “ Company ”), and each of the purchasers identif